Ascendiant Capital Markets Boosts NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $45.00

NRx Pharmaceuticals (NASDAQ:NRXP) had its price target upped by stock analysts at Ascendiant Capital Markets from $44.00 to $45.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other brokerages also recently commented on NRXP. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a report on Monday, November 25th. EF Hutton Acquisition Co. I raised NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st.

NRx Pharmaceuticals Stock Down 6.7 %

NASDAQ NRXP opened at $1.26 on Monday. The firm’s 50-day simple moving average is $1.35 and its two-hundred day simple moving average is $2.08. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $7.33.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC purchased a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned about 0.14% of NRx Pharmaceuticals as of its most recent SEC filing. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.